CLINICAL TRIALS PROFILE FOR NYSTATIN

All Clinical Trials for nystatin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001812 ↗	A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2	Completed	National Cancer Institute (NCI)	Phase 3	1999-04-01	In patients who are receiving intravenous high dose Interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of IL-2, and the second group will receive a placebo. The patients in each group will be monitored and evaluated for differences in the rate and severity of development of oral irritation during treatment. They will also be studied for differences between the two groups in the number of doses of IL-2 taken.
NCT00001998 ↗	Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)	Completed	Argus Pharmaceuticals	N/A	1969-12-31	To define the pharmacokinetic characteristics of Nystatin LF IV (intravenous) in human subjects with AIDS-related complex (ARC) after administration of a single IV dose at each of 4 dose levels.
NCT00002057 ↗	Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC	Completed	Bristol-Myers Squibb	N/A	1969-12-31	To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III or IV, CDC classification).
NCT00002097 ↗	A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.	Completed	Argus Pharmaceuticals	Phase 1	1969-12-31	To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
NCT00002112 ↗	Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome	Completed	Pfizer	N/A	1969-12-31	To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS or HIV infection.

Clinical Trial Conditions for nystatin

Condition Name

Condition Name for nystatin
Intervention	Trials
HIV Infections	6
Candidiasis, Oral	5
Vaginitis	3
Oral Candidiasis	2

Condition MeSH

Condition MeSH for nystatin
Intervention	Trials
Candidiasis	10
Infections	7
Candidiasis, Oral	7
HIV Infections	6

Clinical Trial Locations for nystatin

Trials by Country

Trials by Country for nystatin
Location	Trials
United States	41
Brazil	4
Canada	3
Turkey	2
Spain	2

Trials by US State

Trials by US State for nystatin
Location	Trials
Texas	5
New Jersey	3
Maryland	3
New York	2
Pennsylvania	2

Clinical Trial Progress for nystatin

Clinical Trial Phase

Clinical Trial Phase for nystatin
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	13
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for nystatin
Clinical Trial Phase	Trials
Completed	27
Unknown status	5
Recruiting	2

Clinical Trial Sponsors for nystatin

Sponsor Name

Sponsor Name for nystatin
Sponsor	Trials
Argus Pharmaceuticals	3
National Cancer Institute (NCI)	2
Bristol-Myers Squibb	2

Sponsor Type

Sponsor Type for nystatin
Sponsor	Trials
Other	35
Industry	14
NIH	3